Strategic Alliance Magazine Q2 2017 - 12

COLL ABORATIVE BUZZ

level in a potentially $1 billion
metabolic immune-oncology effort that will take an Agios
MATP pathway candidate into
development. Agios will head research, discovery, and early
development and receive an $8
million designation fee. If Celgene exercises the agreed-upon

I
N
N
O
V
A
T
I
V
E
P
A
R
T
N
E
R
I
N
G

opt-in rights after Phase 1, Agios
will receive another $30 million.
Celgene and Agios Pharmaceuticals would then share a 50/50
costs and profit-sharing arrangement for global development
and commercial rights. "We
have clearly demonstrated our
ability to translate novel Agios
discoveries into important precision medicines in areas of high
unmet needs with our isocitrate
dehydrogenase (IDH) portfolio,"
confirmed Scott Biller, CSO at
Agios Pharmaceuticals. "We look
forward to exploring the potential of our MTAP program in
patients following our expected
IND submission by the end of
this year."
12
STRATEGIC ALLIANCE MAGAZINE | Q2 * 2017

covery safety at AstraZeneca. "That

Detection is the name of
could ultimately be applied to steer
the game for AstraZeneca, away from a potential irritancy hazan ASAP global member, ard and enable the discovery of safer
drugs for patients."
and SenzaGen in a
partnership to create
Britain's
a drug-discovery
GalaxoSmithKline, an
genomic test
ASAP corporate member,
is collaborating with
US-based Regeneron
Pharmaceuticals and the
UK Biobank

to differentiate respiratory allergens
from irritants. The
effort involves AstraZenca's
inhaled
substance libraries to
develop genomic signature
to identify molecules that cause
respiratory tract irritancy and
GARD, SenzaGen's genomic allergen rapid detection platform that
measures genetic biomarkers of
immune reactions to determine
the potential risk of hypersensitivity. "We aim to develop a novel
method to investigate whether
novel drug-like molecules induce
similar genomic signatures as
known respiratory irritants," said
Jorrit Hornberg, director of dis-

to analyze genetic variations and health
in 500,000 middle-aged and older Britons. The volunteers who donated blood
and other samples agreed to have their
health monitored via medical records
over time. The goal is to use Regeneron's gene sequencing center for
analyzing DNA from 50,000 samples
by the end of 2017. AstraZeneca, an
ASAP global member, recently forged a
similar partnership with Craig Venter



Table of Contents for the Digital Edition of Strategic Alliance Magazine Q2 2017

No label
Strategic Alliance Magazine Q2 2017 - No label
Strategic Alliance Magazine Q2 2017 - 2
Strategic Alliance Magazine Q2 2017 - 3
Strategic Alliance Magazine Q2 2017 - 4
Strategic Alliance Magazine Q2 2017 - 5
Strategic Alliance Magazine Q2 2017 - 6
Strategic Alliance Magazine Q2 2017 - 7
Strategic Alliance Magazine Q2 2017 - 8
Strategic Alliance Magazine Q2 2017 - 9
Strategic Alliance Magazine Q2 2017 - 10
Strategic Alliance Magazine Q2 2017 - 11
Strategic Alliance Magazine Q2 2017 - 12
Strategic Alliance Magazine Q2 2017 - 13
Strategic Alliance Magazine Q2 2017 - 14
Strategic Alliance Magazine Q2 2017 - 15
Strategic Alliance Magazine Q2 2017 - 16
Strategic Alliance Magazine Q2 2017 - 17
Strategic Alliance Magazine Q2 2017 - 18
Strategic Alliance Magazine Q2 2017 - 19
Strategic Alliance Magazine Q2 2017 - 20
Strategic Alliance Magazine Q2 2017 - 21
Strategic Alliance Magazine Q2 2017 - 22
Strategic Alliance Magazine Q2 2017 - 23
Strategic Alliance Magazine Q2 2017 - 24
Strategic Alliance Magazine Q2 2017 - 25
Strategic Alliance Magazine Q2 2017 - 26
Strategic Alliance Magazine Q2 2017 - 27
Strategic Alliance Magazine Q2 2017 - 28
Strategic Alliance Magazine Q2 2017 - 29
Strategic Alliance Magazine Q2 2017 - 30
Strategic Alliance Magazine Q2 2017 - 31
Strategic Alliance Magazine Q2 2017 - 32
Strategic Alliance Magazine Q2 2017 - 33
Strategic Alliance Magazine Q2 2017 - 34
Strategic Alliance Magazine Q2 2017 - 35
Strategic Alliance Magazine Q2 2017 - 36
Strategic Alliance Magazine Q2 2017 - 37
Strategic Alliance Magazine Q2 2017 - 38
Strategic Alliance Magazine Q2 2017 - 39
Strategic Alliance Magazine Q2 2017 - 40
Strategic Alliance Magazine Q2 2017 - 41
Strategic Alliance Magazine Q2 2017 - 42
Strategic Alliance Magazine Q2 2017 - 43
Strategic Alliance Magazine Q2 2017 - 44
Strategic Alliance Magazine Q2 2017 - 45
Strategic Alliance Magazine Q2 2017 - 46
Strategic Alliance Magazine Q2 2017 - 47
Strategic Alliance Magazine Q2 2017 - 48
Strategic Alliance Magazine Q2 2017 - 49
Strategic Alliance Magazine Q2 2017 - 50
Strategic Alliance Magazine Q2 2017 - 51
Strategic Alliance Magazine Q2 2017 - 52
https://www.nxtbook.com/allen/stam/23-2
https://www.nxtbook.com/allen/stam/23-1
https://www.nxtbook.com/allen/stam/22-4
https://www.nxtbook.com/allen/stam/22-3
https://www.nxtbook.com/allen/stam/22-2
https://www.nxtbook.com/allen/stam/22-1
https://www.nxtbook.com/allen/stam/21-4
http://www.brightcopy.net/allen/stam/21-3
http://www.brightcopy.net/allen/stam/21-2
http://www.brightcopy.net/allen/stam/21-1
http://www.brightcopy.net/allen/stam/20-4
http://www.brightcopy.net/allen/stam/20-3
http://www.brightcopy.net/allen/stam/20-2
http://www.brightcopy.net/allen/stam/20-1
http://www.brightcopy.net/allen/stam/19-4
http://www.brightcopy.net/allen/stam/19-3
http://www.brightcopy.net/allen/stam/19-2
http://www.brightcopy.net/allen/stam/19-1
http://www.brightcopy.net/allen/stam/18-4
http://www.brightcopy.net/allen/stam/18-3
http://www.brightcopy.net/allen/stam/18-2
http://www.brightcopy.net/allen/stam/18-1
http://www.brightcopy.net/allen/stam/17-4
http://www.brightcopy.net/allen/stam/17-3
http://www.brightcopy.net/allen/stam/17-2
http://www.brightcopy.net/allen/stam/17-1
http://www.brightcopy.net/allen/stam/16-3
http://www.brightcopy.net/allen/stam/16-2
http://www.brightcopy.net/allen/stam/16-1
http://www.brightcopy.net/allen/stam/15-4
http://www.brightcopy.net/allen/stam/15-03
http://www.brightcopy.net/allen/stam/15-02
https://www.nxtbook.com/allen/stam/15-1
https://www.nxtbook.com/allen/stam/14-4
https://www.nxtbook.com/allen/stam/14-3
https://www.nxtbook.com/allen/stam/14-2
https://www.nxtbookmedia.com